BIOMAT Database Logo BIOMAT Database Logo

Methotrexate: mechanism of action, pharmacokinetics, clinical indications, and toxicity. 1991

J Grosflam, and M E Weinblatt
Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Methotrexate has become a standard therapy for the treatment of rheumatoid arthritis. This review summarizes the recent literature on low-dose methotrexate in the rheumatologic illnesses. The effect of methotrexate on in vivo rheumatoid factor production and suppression of ex vivo leukotriene B4 generation is reviewed. New information on drug interactions and pharmacokinetics is highlighted. The efficacy and toxicity of the drug in rheumatoid arthritis and other diseases are further defined. The effects of methotrexate on liver histology are also summarized.

UI MeSH Term Description Entries
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001172 Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. Rheumatoid Arthritis
D012216 Rheumatic Diseases Disorders of connective tissue, especially the joints and related structures, characterized by inflammation, degeneration, or metabolic derangement. Rheumatism,Disease, Rheumatic,Diseases, Rheumatic,Rheumatic Disease

Related Publications

J Grosflam, and M E Weinblatt
[Heparin; mechanism of action and clinical indications].
January 1955, Medicina interna,
J Grosflam, and M E Weinblatt
Alprazolam: pharmacokinetics, clinical efficacy, and mechanism of action.
January 1982, Pharmacotherapy,
J Grosflam, and M E Weinblatt
The mechanism of action, pharmacokinetics and toxicity of acyclovir--a review.
May 1983, The Journal of infection,
J Grosflam, and M E Weinblatt
Cinoxacin: mechanism of action, spectrum of activity, pharmacokinetics, adverse reactions, and therapeutic indications.
January 1982, Pharmacotherapy,
J Grosflam, and M E Weinblatt
Clinical pharmacokinetics of methotrexate.
January 1978, Clinical pharmacokinetics,
J Grosflam, and M E Weinblatt
Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications.
January 1983, Pharmacotherapy,
J Grosflam, and M E Weinblatt
[Methotrexate--mechanism of action and application].
November 2001, Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego,
J Grosflam, and M E Weinblatt
[Action mechanism and clinical indications for thrombocyte aggregation inhibitors].
March 1979, Schweizerische medizinische Wochenschrift,
J Grosflam, and M E Weinblatt
[Mechanism of action, indications and clinical use of nitroglycerin (proceedings)].
January 1978, Fortschritte der Medizin,
J Grosflam, and M E Weinblatt
Anticoagulants: Pharmacokinetics, Mechanisms of Action, and Indications.
October 2018, Neurosurgery clinics of North America,
Copied contents to your clipboard!